Company / Cash & Equivalents
GoodRx Holdings, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$261.8M
FY2025
5-year range
$261.8M / $941.1M
FY2021-FY2025
Trend
-41.6%
vs FY2024
Sector context
#179 of 306
Information Technology
What the data says
At $262M, GoodRx Holdings, Inc.'s cash & equivalents ranks #179 of 306 in the Information Technology sector. Cash & Equivalents has declined for 5 consecutive years, from $969M in FY2020 to $262M in FY2025.
Based on SEC 10-K filings.
$262M in FY2025 with a 5-year CAGR of -23.0%.
Declined from $672M to $262M over the past 2 years.
Information Technology sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.8%
- 5-Year CAGR
- -23.0%
- 10-Year CAGR
- -
Sector benchmark
#179 of 306 in Information TechnologyTop 58% of 306This company $261.8M Sector average $1.3B
▼
-79.7% below sector average
Key checks
Key Insights
- GoodRx Holdings, Inc.'s cash & equivalents has declined for 5 consecutive years.
- 5-year CAGR of -23.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 41.6% year-over-year.
- Ranks #179 out of 306 companies in the Information Technology sector.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $261.8M | -41.6% |
| FY2024 | $448.3M | -33.3% |
| FY2023 | $672.3M | -11.2% |
| FY2022 | $757.2M | -19.5% |
| FY2021 | $941.1M | -2.8% |
| FY2020 | $968.7M | +3618.6% |
| FY2019 | $26.1M | -24.7% |
| FY2018 | $34.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026